Clinical Trials Logo

Clinical Trial Summary

A Phase 1 Dose Escalation and Expanded Cohort Study Of PF-06821497 In The Treatment Of Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) And Follicular Lymphoma (FL).


Clinical Trial Description

This is an open label, multi center, Phase 1 dose escalation and dose expansion study of PF-06821497 administered orally BID as a single agent or in combination with SOC to patients with CRPC, SCLC, and FL. Part 1A will evaluate safety and target modulation of PF-06821497 monotherapy in patients with SCLC, FL and CRPC. PF-06821497 will be administered as monotherapy in patients with FL in Part 1B dose escalation and to patients with CRPC in Part 1C dose escalation. For Part 2A (dose escalation combination therapy), PF-06821497 will be administered in combination with SOC in patients with CRPC and SCLC. For Part 2B (dose expansion), patients with mCRPC will be randomized (1:1 ratio) to receive either SOC or PF-06821497 in combination with SOC. Once safety and adequate target modulation has been established in Part 1A, Parts 1B and 2A of the trial will be initiated. Part 1C (monotherapy dose escalation) will determine the MTD of single agent PF-06821497 in patients with mCRPC. Japan and China monotherapy cohorts will evaluate the safety, antitumor activity and PK of single agent PF-06821497 in Japanese and Chinese patients. Part 2A (escalation RP2D finding for combination) will determine the MTD of the combination with SOC in patients with CRPC. Part 2B (dose expansion) will assess the efficacy of PF-06821497 at the RP2D in combination with SOC in patients with mCRPC in comparison to SOC alone. The study is currently enrolling Part 2B. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03460977
Study type Interventional
Source Pfizer
Contact Pfizer CT.gov Call Center
Phone 1-800-718-1021
Email ClinicalTrials.gov_Inquiries@pfizer.com
Status Recruiting
Phase Phase 1
Start date April 17, 2018
Completion date October 24, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT06043011 - Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Recruiting NCT05409066 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma Phase 3
Terminated NCT03571828 - Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma Phase 1
Terminated NCT02914938 - A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma Phase 1
Recruiting NCT05888493 - A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma Phase 3
Active, not recruiting NCT04049513 - ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) Phase 1
Recruiting NCT06097364 - A Study to Learn How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Compared to Rituximab and Chemotherapy in Adult Participants With Previously Untreated Follicular Lymphoma Phase 3
Recruiting NCT03869619 - REal World Data in LYmphoma and Survival in Adults
Active, not recruiting NCT04830137 - A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies Phase 1
Recruiting NCT03547115 - A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML Phase 1
Not yet recruiting NCT04767308 - Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies Early Phase 1
Terminated NCT03768505 - Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) Phase 2
Recruiting NCT03265158 - Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0 N/A
Enrolling by invitation NCT04488354 - Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T Phase 1
Recruiting NCT05720052 - A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma Phase 1/Phase 2
Recruiting NCT06191744 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma Phase 3
Active, not recruiting NCT02362035 - ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Phase 1/Phase 2
Recruiting NCT06091254 - A Trial to Learn if Odronextamab is Safe and Well-tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma Phase 3
Enrolling by invitation NCT02875548 - A Study to Assess the Long-term Safety of Tazemetostat Phase 1/Phase 2
Active, not recruiting NCT04450069 - CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies Phase 1